

Company name Starget Pharma * Website www.stargetpharma.com*
CEO name Sigal Kalmanson Cusnir
CATEGORY: Biotech/Pharma *
SESSION: Redefining the fight against Cancer: New Targets and Novel Therapeutic Modalities

- Executive Summary / Investment Rational Briefly

Starget Pharma is a radiopharmaceutical company with a differentiated peptide AI-powered platform for rapid discovery of radioligand therapies (RLTs). Our pipeline includes a first-in-class SSTR3 RLT (Phase 1b ,MD Anderson in H2/25) and promising best-in-class CCK2R/GRPR candidates. With \$25MM raised and an experienced management team in peptide drugs, AI and nuclear medicine, we are capitalizing on the booming RLT market.

- Core Technology

Our differentiated in silico AI-powered radioligand discovery platform leverages our proprietary peptide Backbone-Dynamics technology to employ cyclic peptide design and conformational constraints. It simulates peptide folding and stability in silico for precise 3D conformation optimization—critical for binding, metabolic stability, and pharmacokinetics. This approach enhances stability, affinity, selectivity, and drug-like properties, shortening time to human proof-of-concept (18-24 months) and accelerating theranostic efficacy for cancer treatment.

- Product Profile/Pipeline

Our pipeline features a first-in-class SSTR3 RLT for sarcoma, NET, melanoma, and other solid tumors, with Phase 1b planned at MD Anderson in H2 2025. Additionally, promising preclinical data support best-in-class CCK2R and GRPR RLTs for lung, breast, and prostate cancers, with first-in-human trials anticipated within 12 months. Recently emerged from stealth with our platform and discussions with leading pharma companies are taking place.

- Business Strategy

Leveraging our AI-powered peptide RLT platform, we have a broad pipeline addressing the high unmet need for discovering de novo radioligands across a broad range of cancer targets. Our business model combines direct asset commercialization with strategic licensing and collaborations with major pharma companies. This approach accelerates clinical development while creating robust revenue streams and solidifying Starget's leadership in RLT.

- What's Next?

Starget has raised \$25MM to date. Most recently Cancer Focus Fund has invested in the company. Our milestones for the next 18 month is to advance our lead program Lu177-DOTA-PTR58 into Phase 1b studies at MD Anderson, launch first-in-human trials for our GRPR and CCKR2 candidates, and invest in our platform to drive novel pipeline assets and strategic collaborations.